On Friday, Nektar Therapeutics (NASDAQ: NKTR) was 5.90% up from the session before settling in for the closing price of $21.68. A 52-week range for NKTR has been $6.48 – $37.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 25.49%. When this article was written, the company’s average yearly earnings per share was at -27.94%. With a float of $16.86 million, this company’s outstanding shares have now reached $17.30 million.
Let’s determine the extent of company efficiency that accounts for 61 employees. In terms of profitability, gross margin is 74.61%, operating margin of -131.01%, and the pretax margin is -147.55%.
Nektar Therapeutics (NKTR) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Nektar Therapeutics stocks. The insider ownership of Nektar Therapeutics is 2.55%, while institutional ownership is 58.11%. The most recent insider transaction that took place on May 19 ’25, was worth 7,177. In this transaction Chief R&D Officer of this company sold 10,712 shares at a rate of $0.67, taking the stock ownership to the 305,892 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Legal Officer sold 9,996 for $0.67, making the entire transaction worth $6,697. This insider now owns 314,296 shares in total.
Nektar Therapeutics (NKTR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -27.94% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -18.16% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
You can see what Nektar Therapeutics (NKTR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.53, a number that is poised to hit -3.03 in the next quarter and is forecasted to reach -12.31 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Looking closely at Nektar Therapeutics (NASDAQ: NKTR), its last 5-days average volume was 0.6 million, which is a drop from its year-to-date volume of 0.87 million. As of the previous 9 days, the stock’s Stochastic %D was 14.14%.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 53.38%, which indicates a significant increase from 28.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.85 in the past 14 days, which was higher than the 1.64 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.17, while its 200-day Moving Average is $14.94. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $23.63. Second resistance stands at $24.31. The third major resistance level sits at $25.61. If the price goes on to break the first support level at $21.65, it is likely to go to the next support level at $20.35. Should the price break the second support level, the third support level stands at $19.67.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are 12,407K outstanding shares of the company, which has a market capitalization of 397.23 million. As of now, sales total 98,430 K while income totals -118,960 K. Its latest quarter income was 10,460 K while its last quarter net income were -50,880 K.
